Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Microbot Medical Inc.

NASDAQ: MBOT · Industrial Applications and Services · 8 alerts · CIK 883975

Share price
$0.6444Close, Nov 16
Market cap
$43.3M
Shares outstanding
67.16MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Microbot Medical Inc. filings on SEC EDGAR ↗

8:32 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical provided a third quarter 2026 operational update highlighting a 44% sequential increase in procedure utilization for its LIBERTY Endovascular Robotic System. The company ended the quarter with $62 million in cash and expanded its commercial footprint to 12 customer accounts and 10 sales territories.

4:32 PM ET 10-Q
Financial Results

Microbot Medical Q3 2026 Results: Net Loss of $5.84M, Loss Widens

Microbot Medical Inc. reported a net loss of $15.14 million for the nine months ended September 30, 2026, compared to $9.68 million in the prior year, as the company began generating initial revenues of $418,000. Operating expenses increased significantly, particularly in sales and marketing, while cash and marketable securities decreased to approximately $61.8 million.

Key figure
Net loss $5.84M
8:32 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced that the Canadian Intellectual Property Office granted a patent for an adaptor used in its LIBERTY Endovascular Robotic System. This grant brings the company's global intellectual property portfolio to 45 issued patents and 48 pending applications, supporting its strategy for international commercialization expansion.

Counterparty
Canadian Intellectual Property Office
8:31 AM ET 8-K
Contract Win

Microbot Medical Wins Contract from Elmnt Ir

Microbot Medical secured its first Office-Based Laboratory (OBL) customer, ELMNT IR, which signed an order for up to a 12-month supply of the LIBERTY Endovascular Robotic System. This marks the company's first customer on the U.S. West Coast and supports its strategy to expand into outpatient interventional radiology settings.

Counterparty
ELMNT IR
Term
12 months
8:31 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced its attendance at the SIR EDGE 2026 conference and the ACIR Annual Fall Conference to engage with interventional radiologists and hospital administrators. The company aims to leverage these events to generate sales leads and foster adoption of its FDA-cleared LIBERTY Endovascular Robotic System as it expands its U.S. commercial footprint.

8:31 AM ET 8-K
Business Update

Microbot Medical Business Update

Microbot Medical announced it has received several new patent approvals for its LIBERTY Endovascular Robotic System in the U.S., Japan, China, and Canada. The company's global intellectual property portfolio now includes 44 issued patents and 49 pending applications as it pursues commercial expansion and a CE Mark for international markets.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.